Tell Psoriasis Patients When to Expect Peak Response to Cosentyx

May 2015

Cosentyx (koe-SEN-tix, secukinumab) is a new monoclonal antibody for treating moderate to severe plaque psoriasis in adults.

It's the first to inhibit interleukin-17A (IL-17A).

Stelara (ustekinumab) inhibits IL-12 and IL-23...Enbrel (etanercept) and others block tumour necrosis factor.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cultural Awareness Be Aware of Cultural Nuances That Can Impact Patient Communication
Cardiology Help Ensure the Right Aspirin Dose is Used Post-CABG
Cardiology Watch for Patients Using Folic Acid for CV Risk
Psoriasis Tell Psoriasis Patients When to Expect Peak Response to Cosentyx
Women's Health Advise Certain Women to Take a Multivitamin With Iodine
ADHD Help Put Suicide Risks With ADHD Meds Into Perspective
Kidney Stones Recommend Calcium to Help Prevent Kidney Stones
Respiratory & Allergy Recommend Spiriva Before Incruse Ellipta for Moderate COPD
Respiratory & Allergy Recommend Maximizing Other COPD Meds Before Adding Daxas
Wound Care Recommend Ulcer Dressings That Maintain the Right Moisture Level
IBS Don't Jump to SSRIs for Irritable Bowel Symptoms
Sleep Disorders Suggest Patients Wear Sunglasses on the Way Home From Shift Work
Insomnia Discontinue Sedatives on Discharge When Possible
Antibiotics Consider Capping Vancomycin Loading Doses for Obese Patients